Agree with all but your last point. Potential acquirers are focused primarily on Brigatinib. They need product, and Brigatinib is a valuable asset (assuming the data continues to be good).
Regarding Bernie, he did us all a service by pointing out certain problems, but his remedies were, as my two favorite philosophers, Click and Clack, might say, unencumbered by the thought process. Ditto his recent comments on ARIA. People would die without Pona, this is not a commodity drug.